Sat.Jul 09, 2022 - Fri.Jul 15, 2022

article thumbnail

Pharma’s platinum handcuffs

World of DTC Marketing

To address the “retention” problem, pharma companies are paying employees exorbitant salaries. The problem with that system is that people do whatever they need to to “hold onto” their high-paying jobs and become employees who are content not to excel. This is NOT what pharma needs. Last week I briefly chatted with someone in the industry evaluating another job offer.

Pharma 257
article thumbnail

Neuro startups form latest group of grads from PharmStars digital health accelerator

MedCity News

PharmStars, a digital health accelerator, graduated its latest cohort of startups, each of them developing a solution addressing some aspect of neurological disease. The accelerator is accepting applications for the next group of startups for the fall program. The theme is innovations in real-world evidence.

Biopharma 143
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

California’s low-cost insulin plans receive $100m manufacturing boost

Pharmaceutical Technology

Insulin prices made the headlines again as California governor Gavin Newsom announced plans on 7 July for the state to manufacture low-cost insulin. In a budget change proposed in February and confirmed in May , California’s Department of Health Care Access and Information (HCAI) requested a one-time investment of $100 million for Newsom’s CalRx Biosimilar Insulin initiative.

article thumbnail

FDA clears Xalkori for inflammatory myofibroblastic tumours

pharmaphorum

Pfizer’s tyrosine kinase inhibitor Xalkori has picked up a fourth approval from the FDA, adding a new use in the treatment of a rare form of benign tumour that typically affects children and young adults. Xalkori (crizotinib) has been cleared for inflammatory myofibroblastic tumours (IMT), which appear in organs like the lung, stomach, bladder or liver.

FDA 113
article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

article thumbnail

Are digital pharmacies the answer?

World of DTC Marketing

Digital pharmacies seem to be springing up everywhere. Allowing patients to order medications online and get delivery via Fed-Ex or the mail does offer time savings. Still, without a significant value (lower costs), they may not find an audience. Using CVS.com, patients can order medications online and, for a small charge, even deliver them. It’s convenient for most but having a CVS pharmacy on almost every street corner allows patients to use drive-throughs to pick up their medications.

Doctors 245
article thumbnail

RxBenefits, Tria Health form partnership for proactive diabetes care

MedCity News

RxBenefits, a pharmacy benefits optimizer, and Tria Health, a chronic condition and medication management company, have launched a new partnership to improve diabetes care and lower healthcare costs for the condition through a proactive approach. .

More Trending

article thumbnail

Vertex signs agreement to acquire ViaCyte for $320m

Pharmaceutical Technology

Vertex Pharmaceuticals has signed a definitive agreement for the acquisition of biotechnology company ViaCyte in a deal totalling $320m in cash. ViaCyte focuses on offering new stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes (T1D). Through the acquisition, Vertex plans to advance its potentially curative VX-880 programmes in T1D.

article thumbnail

Akili digital therapeutic shows promise in lupus patients

pharmaphorum

Akili looks like it could bring another digital therapeutic (DTx) to market after a clinical trial backed the efficacy of its AKL-T01 in patients with the autoimmune disorder systemic lupus erythematosus (SLE). The PureTech group company – which scored the first FDA and EMA approvals for a DTx for attention-deficit hyperactivity disorder (ADHD) – is developing AKL-T01 to tackle cognitive impairments that can affect people with SLE.

Patients 114
article thumbnail

Solving the nursing crisis starts with psychological safety

MedCity News

When thinking about gratitude for nurses who have carried our nation over the last two-plus years, it’s going to take a lot more than a pizza party during Nurses Month to show them we care.

Safety 128
article thumbnail

Why a 'fundamental shift' in regulatory submissions is on the way

PharmaVoice

Deloitte's senior manager of R&D and regulatory practices explains how technology and strategy must converge to smooth out the bulky drug approval process.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

AI in IVF: a fertile field

Pharmaceutical Technology

Despite entering its fourth decade of availability, in vitro fertilization (IVF), a medical technique used to facilitate the conception of a baby for those facing fertility problems, remains an elusive dream for many. Artificial intelligence (AI) could change this, with many researchers looking to harness the technology to increase IVF’s reliability, affordability, and availability.

Medical 105
article thumbnail

Scott Burrows, Motivational Sales Speaker

Scott Burrows

Where Has Your Motivation Gone? As a former sales advisor with 20 years of experience as a motivational sales speaker, I have an important question: What do you do, when all your motivation has gone? For any salesperson, no matter the field, a lack of motivation is not a luxury.

Sales 98
article thumbnail

Texas sues HHS, claims the agency is trying to turn ERs into abortion clinics

MedCity News

The attorney general of Texas says the recent federal mandates and guidance issued to healthcare providers to protect abortion access are unconstitutional and conflict with state law.

article thumbnail

Janssen extends LGBTQ mental health outreach beyond Pride Month

PharmaVoice

The pharma giant’s ‘Depression looks like me’ campaign assembles a ‘one stop shop’ of resources to help combat high rates of severe depression in the LGBTQ community.

Pharma 98
article thumbnail

How to Stay Competitive in the Evolving State of Martech

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

article thumbnail

Health Canada grants approval for Moderna’s Covid-19 vaccine in children

Pharmaceutical Technology

Health Canada has granted approval for the usage of Moderna’s messenger RNA (mRNA) Covid-19 vaccine, Spikevax, in a 25µg two-dose regimen for active immunisation to prevent Covid-19 in children aged six months to five years. So far, children aged below five years were not eligible to receive the Covid-19 vaccine in Canada. The two-dose initial vaccine regimen in children of this age group is completed in one month, which is the same dosing schedule in adults, adolescents and children aged above

Safety 105
article thumbnail

Preventing the next pandemic: Infrastructure and global equity

pharmaphorum

In the final piece of a three-part series, Ben Hargreaves explores how manufacturing infrastructure was rapidly built up to the required capacity to ensure sufficient supply of COVID-19 vaccines, and what still remains to be done to improve vaccine equity globally. During the early stages of the current pandemic, much of the focus was taken by the possibility of developing a successful vaccine and around the R&D efforts required to achieve this.

article thumbnail

1 in 5 Americans received surprise bills despite law, many lack health insurance literacy, reports find

MedCity News

Skyrocketing medical bills and a lack of understanding in the healthcare system is putting financial stress on Americans in 2022, several recent reports have found. Despite the No Surprises Act, which protects consumers from surprise billing, many Americans said they’re still receiving unexpected bills, and a low healthcare literacy is making it difficult for them to know how to handle high medical bills, the surveys find.

Insurance 122
article thumbnail

Getting Started With Google Analytics 4 for Healthcare Brands

Healthcare Success

Google Analytics is an extremely powerful tool for healthcare businesses. According to BuiltWith, more than 28 million websites use Google Analytics to better understand how users engage with their web properties—including more than 66% of the top 100,000 websites worldwide. The development and subsequent launch of Google Analytics 4 (GA4) in October 2020 was spurred by a 2018 ruling of Europe’s General Data Protection Regulation (GDPR) , the strictest data privacy and security law in the world.

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Merck and Orion enter partnership to develop ODM-208 for prostate cancer

Pharmaceutical Technology

Merck (MSD outside North America) and Orion have entered an international agreement to develop and market the latter’s investigational candidate ODM-208 to treat metastatic castration-resistant prostate cancer (mCRPC). Under the deal, the companies will also develop various other drugs that act on cytochrome P450 11A1 (CYP11A1), an enzyme vital for steroid production.

article thumbnail

Beyond the pill in an outcomes-based world

pharmaphorum

Going beyond the pill is proving to be a win/win for patients and pharma alike – because improved outcomes are better for everyone. With growing numbers of people around the world living with long-term conditions, the pharmaceutical industry has a golden opportunity to use its expertise to truly enhance lives. But innovative new products are only part of the equation, because even the most efficacious drugs will only work as part of a holistic programme of care that includes mental health suppor

Pharma 106
article thumbnail

Novartis turns to algorithms developer Anumana to apply AI to cardio conditions

MedCity News

Novartis is partnering with algorithms startup Anumana to develop a new artificial intelligence-based solution for cardiovascular diseases. The goal is to find ways to detect heart conditions years before symptoms develop in order to enable earlier intervention.

Biopharma 120
article thumbnail

Beat inflation with virtual meetings and programs

Impetus Digital

At the time of writing, the average inflation rate worldwide sits at 7.4% , the highest it’s been for decades. Here in Canada , the inflation rate is not forecasted to come back down to “normal” levels until 2024. As a life science service provider working with companies across the world, we are seeing firsthand how some companies are already tightening their budgets in response to the ongoing economic uncertainty and other world events such as the war in Ukraine.

article thumbnail

Accelerating Clinical Supply Through Integrated Drug Development

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.

article thumbnail

Supply chain & logistics innovation among pharma companies has dropped off in the last year

Pharmaceutical Technology

Research and innovation in supply chain & logistics in the pharmaceutical sector has declined in the last year. The most recent figures show that the number of supply chain and logistics related patent applications in the industry stood at 17 in the three months ending May - down from 21 over the same period in 2021. Figures for patent grants related to supply chain and logistics followed a similar pattern to filings - shrinking from 2 in the three months ending May 2021 to 1 in the same per

Pharma 98
article thumbnail

NICE unlocks use of Amarin’s Vazkepa in 425k NHS patients

pharmaphorum

Health technology assessment (HTA) agency NICE has finalised its guidance on Amarin’s Vazkepa, clearing the path for GPs to start prescribing the drug in up to 425,000 NHS patients at high cardiovascular risk because of raised triglyceride levels. The just-published final technology appraisal document recommends that Vazkepa (icosapent ethyl) can be prescribed to people in England and Wales for adult patients with high-risk cardiovascular disease and elevated levels of triglycerides (1.7 m

article thumbnail

June was a good month for healthcare hiring, but the staffing crisis can only be solved by tech, VBC

MedCity News

Healthcare employment levels are still significantly below what they need to be, and they aren’t on track to get there any time soon. Experts are saying the increased deployment of technology, such as remote patient monitoring and robotic process automation, as well as value-based care models, will be the only sustainable solution to get providers out of this staffing dearth.

article thumbnail

ViiV, Roche and Pfizer top in ESG, according to patients

European Pharmaceutical Review

According to a recent survey of patient groups, Roche, Pfizer, ViiV Healthcare and Gilead Sciences are among the top companies for implementing and reporting progress on environmental, social, governance (ESG) activities. However the survey of 1,500 patient groups also found that 55 percent were not aware of pharma’s ESG programmes, suggesting pharma needs to better include and consider the patient perspective in establishing their ESG goals.

article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

FACTOR AFFECTING ON THE DANDRUFF GROWTH AND THE IMPACT OF NATURAL HERBS AS AN ANTI-DANDRUFF AGENT

Pharmatutor

FACTOR AFFECTING ON THE DANDRUFF GROWTH AND THE IMPACT OF NATURAL HERBS AS AN ANTI-DANDRUFF AGENT. About Authors. Avdesh Thassu. MPharm.(Nat. Chem.); MBA (Mkt.). Associate Vice President. Global Regulatory Affairs, Emami Limited, 7044455199. athassu@hotmail.com. Chandra Mohan Nandi. MSc.(Med. Chem.). Deputy Manager, Global Regulatory Affairs, Emami Limited, 9051706947. chandramohannandi@yahoo.in. admin.

article thumbnail

New York says Teva lied about role in opioid epidemic

pharmaphorum

New York’s attorney general has accused Teva of lying to evade responsibility for its alleged role in fuelling the opioid epidemic in the state and is asking for a case against the company to be reopened. AG Letitia James says the Israeli drugmaker “made significant and intentional misrepresentations” to her office and the court about its involvement with its US subsidiary in order to evade legal action and accountability.

Marketing 102
article thumbnail

The financial journey in healthcare

MedCity News

Employee health benefits is the theme of the MedCity INVEST Digital Health conference in Dallas, scheduled for September 28, in collaboration with Health Wildcatters. Register today.

article thumbnail

Ensuring adequate sanitisation: disinfectant-resistant microbes in cleanrooms

European Pharmaceutical Review

Microbes developing resistance to disinfectants is a major emerging problem in pharmaceutical manufacturing cleanrooms and, if left unchecked, could present a threat to drug quality and, therefore, human health. More than 480 warning letters solely related to the failure to produce aseptic conditions because of deficient cleaning and disinfection systems for cleanrooms and their equipment, were issued by regulators between 2013 to 2018.

article thumbnail

ABM Evolution: How Top Marketers Are Using Account-Based Strategies

In times of economic uncertainty, account-based strategies are essential. According to several business analysts and practitioners, ABM is a necessity for creating more predictable revenue. Research shows that nearly three-quarters of marketers (74%) already have the resources needed to build successful ABM programs.